Pricing Panacea Or PR Victory? Expedited US ANDAs May Have Limited Impact
This article was originally published in PharmAsia News
Executive Summary
In theory, reviewing US generic applications faster should speed competition; in practice, the FDA's new policy likely won't make too much difference.